The management of HPV-related cervical precancer based on the HPV genotypes and involvement of human immune responses on its progression

DOI Web Site 22 References
  • Taguchi Ayumi
    Department of Obstetrics and Gynecology, The University of Tokyo (Hongou 7-3-1, Bunkyo-ku, Tokyo 113-8655, JAPAN)
  • Kawana Kei
    Department of Obstetrics and Gynecology, Nihon University (Ooyaguchikamimachi 30-1, Itabashi-ku, Tokyo, 173-8610, JAPAN)

Bibliographic Information

Other Title
  • HPV感染病変の段階的管理におけるHPVジェノタイプの意義と 免疫の関与について

Search this article

Abstract

<p> HPV infection is the primary cause of cervical cancer and its precancer. With popularization of HPV prophylactic vaccines, the incidence of cervical cancer is expected to decrease, however, it will take time to eradicate cervical cancer. In order to prevent and control cervical cancer, it is important to implement a step-by-step preventive strategy according to the level of prevention: the primary prevention by HPV prophylactic vaccines; the secondary prevention by screening and treatment; and the tertiary prevention by the treatment of invasive cervical cancer. In this review, we especially focus on the secondary prevention and discuss the management of HPV-related cervical precancer based on the HPV genotypes as well as human immune responses against HPV infection.</p>

Journal

References(22)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top